The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients.
Dhooge PPA, Möller PT, Boon CJF, Lotery AJ, Herrmann P, Battaglia Parodi M, Klein W, Fsadni MG, Wheeler-Schilling TH, Jungmann O, Müller H, Holz FG, Schmitz-Valckenberg S, Peters TM, Stingl K, Hoyng CB; Soraprazan Consortium.
Dhooge PPA, et al. Among authors: wheeler schilling th.
Open Res Eur. 2022 Sep 27;1:96. doi: 10.12688/openreseurope.13872.3. eCollection 2021.
Open Res Eur. 2022.
PMID: 37645124
Free PMC article.